[...] To view or add a comment, sign in Eli Lilly's VERVE-102, an investigational single-dose gene-editing medicine, shows groundbreaking potential as a one-time treatment for hypercholesterolemia by durably reducing LDL cholesterol by up to 62% and PCSK9 by up to 88% in the Phase 1b Heart-2 trial
She was 46
However, semaglutide has a longer track record and more long-term safety data
Symptom onset ranged from 2 to 39 days after vaccination, with common clinical features including palpitations, weight loss, heat intolerance, tremors, fatigue, and anxietytypical manifestations of hyperthyroidism
It must be emphasized that effects in humans on hair follicle health are not as dramatic
Customer care rounds out the assessment